Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 13 art units • 20 examiners • 0 of 20 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Oregon Health & Science University maintains a portfolio with 20 pending office actions concentrated in the Biotechnology & Pharmaceuticals technology area. This workload is spread across 13 distinct art units, demonstrating a broad reach within the relevant technical fields at the patent office. The university is currently interacting with 20 distinct examiners, which matches the total number of pending office actions.
The distribution of cases is highly individualized, as evidenced by the fact that the busiest examiner, TON, MARTIN TRUYEN, is managing only 1 busiest examiner pending action. The matching count of distinct examiners and pending office actions suggests a lack of examiner-level concentration in the current prosecution phase. Every pending matter is assigned to a different individual, as no single examiner holds more than 1 busiest examiner pending action.
For patent practitioners, this data shows that the pending office actions are being evaluated by a wide variety of personnel across 13 distinct art units. Strategies for responding to these actions must be tailored to the specific perspectives of the different examiners, as the workload is not concentrated under any single person.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (25%) |
| §103 only | 4 (20%) |
| §102 only | 1 (5%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 2 (10%) |
| Multi-statute (no §101) | 7 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TON, MARTIN TRUYEN | 1 | 62.3% | +34.3% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| NOGUEROLA, ALEXANDER STEPHAN | 1 | 82.7% | +3.0% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
| STEELE, AMBER D | 1 | 58.9% | +9.3% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| PHAM, KHAI QUYNH TIEN | 1 | 0.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | — |
| 18579830 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | INAM, SAHAR | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18316719 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA | JOHANNSEN, DIANA B | 134d overdue |
| 17114433 | PREDICTING AND PREVENTING HYPOGLYCEMIA IN PATIENTS HAVING TYPE 1 DIABETES DURING PERIODS OF INCOGNIZANCE USING BIG DATA ANALYTICS AND DECISION THEORETIC ANALYSIS | GIRI, PURSOTTAM | 14d |
| 18992663 | METHODS AND SYSTEMS FOR TRANS-CERVICAL DELIVERY OF AGENTS | TON, MARTIN TRUYEN | — |
| 18834945 | METHODS AND SYSTEMS FOR SORTING PARTICLES IN FLUIDS | NOGUEROLA, ALEXANDER STEPHAN | — |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | — |
| 18290740 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | STEELE, AMBER D | — |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | DONOHUE, SEAN R | — |
| 18575219 | WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING | WESTERBERG, NISSA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18992663 | METHODS AND SYSTEMS FOR TRANS-CERVICAL DELIVERY OF AGENTS | TON, MARTIN TRUYEN | — |
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | — |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | — |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | DONOHUE, SEAN R | — |
| 18575219 | WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING | WESTERBERG, NISSA M | — |
| Art Unit | Apps |
|---|---|
| 3771 | 2 |
| 1684 | 2 |
| 1795 | 1 |
| 1685 | 1 |
| 1622 | 1 |
| 1764 | 1 |
| 1682 | 1 |
| 1618 | 1 |
| 1626 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18992663 | METHODS AND SYSTEMS FOR TRANS-CERVICAL DELIVERY OF AGENTS | TON, MARTIN TRUYEN | 3771 | §102§103§112 | Non-Final OA | — | Pending | Jan 09, 2025 |
| 18823280 | TARGETED NANOCARRIERS FOR SYSTEMIC DELIVERY OF IRAK4 INHIBITORS TO INFLAMED TISSUES | VARADARAJ, ARCHANA | — | §103 | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18795621 | DERIVATIVES OF SOBETIROME | JACKSON, SHAWQUIA | — | §112Other | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18834945 | METHODS AND SYSTEMS FOR SORTING PARTICLES IN FLUIDS | NOGUEROLA, ALEXANDER STEPHAN | 1795 | §102§103 | Final Rejection | — | Pending | Jul 31, 2024 |
| 18292884 | METHODS FOR SELECTING MELANOMA PATIENTS FOR THERAPY AND METHODS OF REDUCING OR PREVENTING MELANOMA METASTASIS | GUSSOW, ANNE | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18290740 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | STEELE, AMBER D | — | §101§102§103§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18290755 | Self-assembling nanomaterial for the detection, imaging, or treatment of cancer | DONOHUE, SEAN R | — | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18579830 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18575219 | WATER-SOLUBLE NERVE DYES FOR IN VIVO NERVE-SPECIFIC IMAGING | WESTERBERG, NISSA M | — | §102DP | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18548864 | MOLECULAR BARCODES AND RELATED METHODS AND SYSTEMS | PHAM, KHAI QUYNH TIEN | 1684 | §102§112 | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18269150 | ANTIBACTERIAL ESTER-FREE MONOMERS FOR DENTAL ADHESIVES | KELLY-O'NEILL, YOLANDA LYNNETTE | 1764 | §103 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18316719 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA | JOHANNSEN, DIANA B | 1682 | §101§102§103§112 | Non-Final OA | 134d overdue | Pending | May 12, 2023 |
| 18248045 | Zwitterionic Cell-Permeant and Water-Soluble Rhodamine Dyes for Quantitative Imaging Applications | SCHLIENTZ, LEAH H | 1618 | §102§103 | Final Rejection | — | Pending | Apr 05, 2023 |
| 18122605 | SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP) | AGUIRRE, AMANDA L | 1626 | §102 | Final Rejection | — | Pending | Mar 16, 2023 |
| 18025489 | AUXETIC DEVICE DELIVERY APPARATUS AND METHOD | HOUSTON, ELIZABETH | 3771 | §102§103 | Non-Final OA | — | Pending | Mar 09, 2023 |
| 17909908 | MECHANISTIC BIOMARKER FOR PREDICTING THE SURVIVAL OF PANCREATIC CANCER PATIENTS | TSAY, MARSHA M | 1656 | §101§112 | Final Rejection | — | Pending | Sep 07, 2022 |
| 17786186 | MULTI-SPECIFIC T CELL RECEPTORS | PETERS, ALEC JON | 1641 | §103DP | Final Rejection | 73d overdue | Pending | Jun 16, 2022 |
| 17753592 | CRISPR-MEDIATED CAPTURE OF NUCLEIC ACIDS | YOUNG, BRIAN ELLIS | 1684 | §103§112 | Non-Final OA | — | Pending | Mar 08, 2022 |
| 17616941 | TUMOR-ASSOCIATED ANTIGEN-SPECIFIC T CELL RESPONSES | BERHANE, SELAM | 1675 | §103 | Final Rejection | 4d overdue | Pending | Dec 06, 2021 |
| 17114433 | PREDICTING AND PREVENTING HYPOGLYCEMIA IN PATIENTS HAVING TYPE 1 DIABETES DURING PERIODS OF INCOGNIZANCE USING BIG DATA ANALYTICS AND DECISION THEORETIC ANALYSIS | GIRI, PURSOTTAM | 2186 | §101§102§103 | Non-Final OA | 14d | Pending | Dec 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial